Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells in Haploidentical HSCT
NCT03106662Phase 3Completed
- Sponsor
- Ankara University
- Start
- Oct 2014
- Primary completion
- Jul 2017
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mesenchymal stem cells in hematologic malignancy, sponsored by Ankara University. Primary endpoint: Overall Survival at 36 months. Started Oct 2014; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03106662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106662.